Aluminium phosphate
Identification
- Generic Name
- Aluminium phosphate
- DrugBank Accession Number
- DB14517
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Aluminium phosphate (DB14517)
- Weight
- Average: 121.9529
Monoisotopic: 121.934958441 - Chemical Formula
- AlO4P
- Synonyms
- Aluminum phosphate
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot.
Target Actions Organism USerotransferrin Not Available Humans USodium/potassium-transporting ATPase subunit alpha-1 Not Available Humans UKallikrein-1 Not Available Humans UAmyloid beta A4 protein Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetaminophen Aluminium phosphate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Acetophenazine Aluminium phosphate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium phosphate. Alimemazine Aluminium phosphate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Allopurinol The therapeutic efficacy of Allopurinol can be decreased when used in combination with Aluminium phosphate. Amphetamine The serum concentration of Amphetamine can be increased when it is combined with Aluminium phosphate. Amprenavir Aluminium phosphate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Asunaprevir Aluminium phosphate can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. Atazanavir Aluminium phosphate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Beclomethasone dipropionate The bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminium phosphate. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- No interactions found.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Gelfos Gel 61.9 g/100g Oral Boryung Pharmaceutical Co., Ltd 2015-04-18 2016-12-12 US 
Gelfos M Gel 61.9 g/100g Oral Boryung Pharmaceutical Co., Ltd 2015-04-18 2016-12-12 US Gelfos M Gel 61.9 g/100g Oral Boryung Pharmaceutical Co., Ltd 2016-02-28 2016-04-11 US Gelfose Gel 61.9 g/100g Oral Boryung Pharmaceutical Co., Ltd 2015-03-08 2016-12-12 US Gelfose M Gel 61.9 g/100g Oral Boryung Pharmaceutical Co., Ltd 2015-03-08 2016-12-12 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Gelfos M Aluminium phosphate (61.9 g/100g) + Dimethicone (0.2 g/100g) + Magnesium hydroxide (2 g/100g) Gel Oral Boryung Pharmaceutical Co., Ltd 2016-02-28 2016-12-12 US Gelfos M Aluminium phosphate (12.38 g/20g) + Dimethicone (0.04 g/20g) + Magnesium hydroxide (0.4 g/20g) Gel Oral Boryung Pharmaceutical Co., Ltd. 2017-01-01 2016-12-12 US Gelfos M Aluminium phosphate (12.38 g/20g) + Dimethicone (0.04 g/20g) + Magnesium hydroxide (0.4 g/20g) Suspension Oral Boryung Pharmaceutical Co., Ltd. 2017-01-01 2017-04-03 US Gelfos-M Aluminium phosphate (12.38 g/20g) + Dimethicone (40 mg/20g) + Magnesium hydroxide (400 mg/20g) Liquid Oral OASIS TRADING 2018-11-15 Not applicable US Gelfos-M Aluminium phosphate (12.38 g/20g) + Dimethicone (40 mg/20g) + Magnesium hydroxide (400 mg/20g) Liquid Oral I World Pharmaceutical Co., Ltd. 2019-10-08 Not applicable US Gelfos-M Aluminium phosphate (12.38 g/20g) + Dimethicone (40 mg/20g) + Magnesium hydroxide (400 mg/20g) Liquid Oral LYDIA Co., Ltd 2019-10-08 Not applicable US PRIMPERAN GEL Aluminium phosphate (4.5 g) + Metoclopramide hydrochloride (0.07 g) + Simethicone (0.25 g) Suspension Oral 2008-01-21 2021-07-01 Colombia 
Categories
- ATC Codes
- A02AB03 — Aluminium phosphate
- Drug Categories
- Acids
- Acids, Noncarboxylic
- Adjuvants, Immunologic
- Alimentary Tract and Metabolism
- Aluminium Compounds
- Aluminum and magnesium containing antacids
- Anions
- Antacids
- Drugs for Acid Related Disorders
- Electrolytes
- Gastric Acid Lowering Agents
- Gastrointestinal Agents
- Immunologic Factors
- Ions
- Metal cations
- Metal divalent cations
- Phosphoric Acids
- Phosphorus Acids
- Phosphorus Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as post-transition metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is a post-transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Post-transition metal oxoanionic compounds
- Sub Class
- Post-transition metal phosphates
- Direct Parent
- Post-transition metal phosphates
- Alternative Parents
- Post-transition metal salts / Inorganic salts / Inorganic oxides
- Substituents
- Inorganic oxide / Inorganic post-transition metal salt / Inorganic salt / Post-transition metal phosphate
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- F92V3S521O
- CAS number
- 7784-30-7
- InChI Key
- ILRRQNADMUWWFW-UHFFFAOYSA-K
- InChI
- InChI=1S/Al.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+3;/p-3
- IUPAC Name
- aluminium(3+) phosphate
- SMILES
- [Al+3].[O-]P([O-])([O-])=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 58204
- ChEMBL
- CHEMBL3833315
- Wikipedia
- Aluminium_phosphate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Diphtheria / Pertussis / Tetanus 1 3 Completed Prevention Haemophilus Influenzae Type b (Hib) Infection 1 3 Completed Prevention Immunizations 1 2 Completed Prevention Enterovirus 71 Human 1 2 Completed Prevention Meningococcal Disease 1 2 Completed Prevention Respiratory Syncytial Virus (RSV) 1 1 Completed Prevention Cytomegalovirus (CMV) Infection 1 1 Completed Prevention Plasmodium Falciparum Malaria 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gel Oral Gel Oral Suspension Oral Liquid Oral Gel Oral 61.9 g/100g Injection, suspension Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1 ChemAxon pKa (Strongest Acidic) 1.8 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 86.25 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 11.29 m3·mol-1 ChemAxon Polarizability 4.93 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transferrin receptor binding
- Specific Function
- Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
- Gene Name
- TF
- Uniprot ID
- P02787
- Uniprot Name
- Serotransferrin
- Molecular Weight
- 77063.195 Da
References
- Nolte E, Beck E, Winklhofer C, Steinhausen C: Compartmental model for aluminium biokinetics. Hum Exp Toxicol. 2001 Feb;20(2):111-7. [PubMed:11327511]
- Nagaoka MH, Maitani T: Binding affinity of aluminium to human serum transferrin and effects of carbohydrate chain modification as studied by HPLC/high-resolution ICP-MS--speciation of aluminium in human serum. J Inorg Biochem. 2005 Sep;99(9):1887-94. [PubMed:16139893]
- Mizutani K, Mikami B, Aibara S, Hirose M: Structure of aluminium-bound ovotransferrin at 2.15 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1636-42. Epub 2005 Nov 19. [PubMed:16301797]
- Beardmore J, Rugg G, Exley C: A systems biology approach to the blood-aluminium problem: the application and testing of a computational model. J Inorg Biochem. 2007 Sep;101(9):1187-91. Epub 2007 Jun 12. [PubMed:17629565]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Menz RI, Walker JE, Leslie AG: Structure of bovine mitochondrial F(1)-ATPase with nucleotide bound to all three catalytic sites: implications for the mechanism of rotary catalysis. Cell. 2001 Aug 10;106(3):331-41. [PubMed:11509182]
- Silva VS, Goncalves PP: The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. [PubMed:14507470]
- Amador FC, Santos MS, Oliveira CR: Lipid peroxidation and aluminium effects on the cholinergic system in nerve terminals. Neurotox Res. 2001 Jul;3(3):223-33. [PubMed:15111247]
- Kohila T, Parkkonen E, Tahti H: Evaluation of the effects of aluminium, ethanol and their combination on rat brain synaptosomal integral proteins in vitro and after 90-day oral exposure. Arch Toxicol. 2004 May;78(5):276-82. [PubMed:15254985]
- Kohila T, Tahti H: Effects of aluminium and lead on ATPase activity of knockout +/- mouse cerebral synaptosomes in vitro. Altern Lab Anim. 2004 Oct;32(4):361-7. [PubMed:15651920]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
- Gene Name
- KLK1
- Uniprot ID
- P06870
- Uniprot Name
- Kallikrein-1
- Molecular Weight
- 28889.425 Da
References
- De Sousa MO, Santoro MM, De Souza Figueiredo AF: The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. J Enzyme Inhib Med Chem. 2004 Aug;19(4):317-25. [PubMed:15558947]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transition metal ion binding
- Specific Function
- Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and tra...
- Gene Name
- APP
- Uniprot ID
- P05067
- Uniprot Name
- Amyloid beta A4 protein
- Molecular Weight
- 86942.715 Da
References
- Banks WA, Niehoff ML, Drago D, Zatta P: Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. Brain Res. 2006 Oct 20;1116(1):215-21. Epub 2006 Aug 30. [PubMed:16942756]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Zatta P, Dalla Via L, Di Noto V: Binding studies on aluminum(III)-albumin interaction. Arch Biochem Biophys. 2003 Sep 1;417(1):59-64. [PubMed:12921780]
Drug created on July 12, 2018 16:38 / Updated on June 12, 2020 16:53